Noble Financial Keeps Agile Therapeutics (AGRX) at 'Buy'; Q2 Results Inline, Key Phase 3 Data Expected in Q4
Go back to Noble Financial Keeps Agile Therapeutics (AGRX) at 'Buy'; Q2 Results Inline, Key Phase 3 Data Expected in Q4| Loomis Sayles Mid Cap Growth Fund Retail Class (NASDAQ: AGRX) | Delayed: 0.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.60 | 52 Week High | $10.41 | |||
| Open | $0.60 | 52 Week Low | $5.32 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.60 | EPS | $0.00 | |||
| Volume | 85,721 | |||||
